Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902

Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902

Introduction: Treatment strategies that enhance the efficacy of immunotherapy are desired. Radiotherapy can enhance immunity, but the utility of adding radiotherapy to immunotherapy plus platinum-doubled chemotherapy in patients with metastatic NSCLC has not been explored. Methods: This multicenter,...

Full description

Saved in:
Bibliographic Details
Main Authors: Yoko Tsukita, MD, PhD, Rei Umezawa, MD, PhD, Taku Nakagawa, MD, PhD, Akira Anbai, MD, PhD, Tomonori Makiguchi, MD, PhD, Hisashi Tanaka, MD, PhD, Yosuke Horii, MD, PhD, Aya Suzuki, MD, Ryo Morita, MD, PhD, Hitomi Nogawa, MD, Hiroshi Yokouchi, MD, PhD, Nozomu Kimura, MD, PhD, Keiichi Jingu, MD, PhD, Akira Inoue, MD, PhD, Hisatoshi Sugiura, MD, PhD, Eisaku Miyauchi, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:JTO Clinical and Research Reports
Subjects:
NSCLC
Radiotherapy
Abscopal
Pembrolizumab
Chemotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000335
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666364325000335

Similar Items